USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Aastrom Biosciences, Inc.
Address:
Domio'S Farms. Lobby L, 24 Frank Lloyd Wright Dr.
Ann Arbor, MI 48105
Phone:
(734) 930-5555
URL:
N/A
EIN:
943096597
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,761,886.00 17
SBIR Phase II $4,270,825.00 7

Award List:

Clonal Hematopoietic Progenitor Cell Assay

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Manfred R. Koller
Abstract:
Hematopoiesis, the regulated production of mature blood cells, is a complex scheme of multilineage differentiation which occurs mainly in the bone marrow of adult mammals. Mature cells are continuously produced from progenitor (or precursor) cells. Consequently, assays which detect these progenitor… More

Hematopoietic Cell Expansion System

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Douglas R. Armstrong
Abstract:
N/a

Hematopoietic Cell Expansion System

Award Year / Program / Phase:
1995 / SBIR / Phase II
Award Amount:
$520,371.00
Agency:
HHS
Principal Investigator:
Douglas R. Armstrong
Abstract:
Bone marrow transplant (BMT) is an extraordinarily rapidly growing field, and the number of transplants in the U. S. is expected to grow from a current rate of 15,000 per year to over 100,000 per year by 1995. This rapid expansion is due to the diversity in the types of bone marrow transplantation… More

Expansion of Stem Cells From CD34-Enriched Populations

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$70,948.00
Agency:
HHS
Principal Investigator:
Manfred Koller
Abstract:
In vitro expansion of hematopoietic cells finds many applications in the clinic. This technique hasexpanding CD34+ cells for transplantation/re infusion, although most of the technology has consistedcultures in which there is variable CFUGM expansions and failure to maintain LTC IC (long term… More

EXPANSION OF HUMAN UMBILICAL CORD BLOOD STEM CELLS

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$98,102.00
Agency:
HHS
Principal Investigator:
Smith, alan k
Abstract:
N/a

Expansion of Stem Cells From CD34-Enriched Populations

Award Year / Program / Phase:
1998 / SBIR / Phase II
Award Amount:
$736,510.00
Agency:
HHS
Principal Investigator:
Manfred Koller
Abstract:
In vitro expansion of hematopoietic cells finds many applications in the clinic. This technique hasexpanding CD34+ cells for transplantation/re infusion, although most of the technology has consistedcultures in which there is variable CFUGM expansions and failure to maintain LTC IC (long term… More

CLINICAL SCALE EXPANSION OF HUMAN DENDRITIC CELLS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$98,825.00
Agency:
HHS
Principal Investigator:
Smith, Douglas M
Abstract:
N/a

EXPANSION OF HUMAN UMBILICAL CORD BLOOD STEM CELLS

Award Year / Program / Phase:
1998 / SBIR / Phase II
Award Amount:
$769,484.00
Agency:
HHS
Principal Investigator:
Smith, alan k
Abstract:
N/a

EXPANSION AND GENETIC TRANSDUCTION OF EBV-SPECIFIC CTLS

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$99,805.00
Agency:
HHS
Principal Investigator:
Douglas M. Smith
Abstract:
Not Available Differential absorption lidar (DIAL) systems have become extremely useful tools for remote sensing of atmospheric constituents. Physical Sciences Inc. proposes to develop a compact, lightweight, quantum cascade (QC) laser-based DIAL transceiver for remote sensing of airborne chemical… More

MEGAKARYOCYTE EXPANSION FROM MOBILIZED PERIPHERAL BLOOD

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$99,839.00
Agency:
HHS
Principal Investigator:
Alan K. Smith
Abstract:
N/a

STROMAL EFFECTS ON UMBILICAL CORD BLOOD EXPANSION

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$105,456.00
Agency:
HHS
Principal Investigator:
Alan K. Smith
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Kristin L. Goltry
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$368,781.00
Agency:
HHS
Principal Investigator:
Kristin L. Goltry
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Douglas M. Smith
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$334,347.00
Agency:
HHS
Principal Investigator:
Douglas M. Smith
Abstract:
N/a

Clinical Human Cell Production System for Broad Use

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$101,452.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): As a result of growing evidence of their therapeutic potential in cancer, infectious diseases, and tissue repair, there is an enormous increase in the research and discovery of cell-based medical treatments that require cultured cells. A large unmet need exists… More

Enhanced Tumor Antigen Priming of Dendritic Cell Vaccine

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$101,262.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by the applicant): Dendritic cells have been shown to initiate, regulate, and direct cytolytic T-cell-mediated immune responses against tumor antigens in human patients. Recent clincal trials have demonstrated induction of clinically significant immune responses against… More

Automated Perfused Culture Process for Adult Stem Cells

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$442,555.00
Agency:
HHS
Principal Investigator:
Kristin L. Goltry
Abstract:
DESCRIPTION (provided by applicant): Adherent mesenchymal cell populations derived from bone marrow (BM) have the capability of differentiating into multiple cell lineages in vitro and in vivo. The potential use of these populations, referred to as marrow stromal cells (MSC), in clinical… More

Clinical-scale Production of Osteoprogenitor Cells

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$110,062.00
Agency:
HHS
Principal Investigator:
Kristin L. Goltry
Abstract:
DESCRIPTION (provided by applicant): Due to morbidity and limited amounts of material, alternatives to autologous grafts for bone repair are desirable. Mixtures of marrow stromal cells (MSC) and carrier matrices are known to augment bone repair. Increasing the number of MSC through ex vivo… More

Automated Large-Scale Production of Endothelial Cells

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$99,840.00
Agency:
HHS
Principal Investigator:
Kristin L. Goltry
Abstract:
DESCRIPTION (provided by applicant): Treatment of ischemia by administration of bone marrow (BM)-derived endothelial progenitor cells (EPC) or ex vivo expanded EPC populations has been shown to enhance vascular regeneration in animal models and in clinical trials. For cell therapy to be practical in… More

Dendritic Cell Subset for Enhanced Cancer Vaccine

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$109,586.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Tumor antigen primed dendritic cells (DCs) are under widespread clinical evaluation for immunotherapy of multiple forms of cancer. Emerging evidence suggests that DCs are fundamental regulators of the immune response leading to potent cell mediated immunity or… More

Bioreactor for Enhanced T-cell Based Therapy of Melanoma

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$124,154.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Malignant melanoma is a significant and deadly form of cancer worldwide. Emerging evidence has shown that melanoma cells express tumor-associated antigens that are specifically recognized by the immune system. Melanoma antigen-specific T-lymphocytes can be… More

Clinical-scale Production of Osteoprogenitor Cells

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$743,066.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Due to morbidity and limited amounts of material, alternatives to autologous grafts for bone repair are desirable. Cells within the bone marrow are known to possess bone regenerative capacity, but they are limited in number. Increasing these osteoprogenitor cell… More

Clinical Human Cell Production System for Broad Use

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$798,266.00
Agency:
HHS
Principal Investigator:
Abstract:
The therapeutic potential of patient-specific cultured cells continues to rapidly grow for a range of medical needs, such as regenerative repair of damaged tissue, cancer, and infectious diseases. As a result, the motivation to commercialize patient-specific "cell products" is increasing rapidly as… More